CONSULTANT HAEMATOLOGIST
Dr Zane Kaplan
MBBS(Hons) BMedSci(Hons) PhD FRACP FRCPA
Dr Zane Kaplan is a Consultant Haematologist in the Department of Haematology at Monash Health and the Alfred Hospital. He is also the head of the Victorian Haemoglobinopathy and Haemophilia Reference Laboratory and Haemoglobinopathy Service at Monash Health.
Dr Kaplan graduated from Monash University and completed his physician training in internal medicine at the Alfred Hospital. He completed his clinical and laboratory haematology training at the Alfred and Royal Melbourne Hospitals and subsequently undertook a haematology research fellowship at Monash Health. Dr Kaplan has also undertaken a Doctor of Philosophy (PhD) through Monash University at the Australian Centre for Blood Diseases, focusing on platelet biology and immunology.
Practice Interests
Dr Zane Kaplan has general haematology interests with a specific focus on haemostasis and thrombosis and platelet disorders, as well as anaemia and haemoglobinopathies. Dr Kaplan is happy to be referred patients with non-malignant and malignant haematological disorders. Dr Kaplan adopts a holistic approach to patient care.
Dr Kaplan is actively involved in clinical trials with a particular focus on red cell disorders, iron overload and immune thrombocytopenia. Dr Kaplan is also involved in translational research to help to identify and develop novel therapies for patients with haemoglobinopathies.
Practice Locations
Dr Zane Kaplan consults privately in rooms located within Monash Specialist Centre, Clayton.
TeleHealth appointments are available.
Monash Specialist Centre
Suite 10
212-220 Clayton Rd
Clayton VIC 3168
Tel: 03 9544 6448
Fax: 03 8610 2177
Hospital Accreditation
Clinical Interests Include:
Extended Profile
Dr Zane Kaplan
– Key Research, Journal & Book Publications, Presentations &/or Awards
Selected Journal Publications
Dr Kaplan is actively involved in clinical trials with a particular focus on red cell disorders, iron overload and immune thrombocytopenia. Dr Kaplan is also involved in translational research to help to identify and develop novel therapies for patients with haemoglobinopathies.
- Ong J, Bowden D, Kaplan Z.. Management of haemoglobin Barts hydrops fetalis syndrome with exchange transfusions. Intern Med J. 2020 May;50(5):638-639.
- McQuilten ZK, Higgins AM, Burns K, Chunilal S, Dunstan T, Haysom HE, Kaplan Z, Rushford K, Saxby K, Tahiri R, Waters N, Wood EM.The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. Transfusion. 2019 Nov;59(11):3386-3395.
- Premawardena C, Bowden D, Kaplan Z, Dendle C, Woolley IJ. Understanding of the significance and health implications of asplenia in a cohort of patients with haemaglobinopathy: possible benefits of a spleen registry. Hematology. 2018 Sep;23(8):526-530.
- Yii E, Doery JC, Kaplan Z, Kerr PG. Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients. Nephrology (Carlton). 2018 Sep;23(9):887-889.
- Yuan Y, Alwis I, Wu MCL, Kaplan Z, Ashworth K, Bark D Jr, Pham A, Mcfadyen J, Schoenwaelder SM, Josefsson EC, Kile BT, Jackson SP.Neutrophil macroaggregates promote widespread pulmonary thrombosis after gut ischemia. Sci Transl Med. 2017 Sep 27;9(409):eaam5861.
- McFadyen JD, Tran H, Kaplan ZS. Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A. Br J Haematol. 2017 Sep;178(6):986-987.
- Brazilek RJ, Tovar-Lopez FJ, Wong AKT, Tran H, Davis AS, McFadyen JD, Kaplan Z, Chunilal S, Jackson SP, Nandurkar H, Mitchell A, Nesbitt WS. Application of a strain rate gradient microfluidic device to von Willebrand’s disease screening. Lab Chip. 2017 Jul 25;17(15):2595-2608.
- Gurry GA, Campion V, Premawardena C, Woolley I, Shortt J, Bowden DK, Kaplan Z, Dendle C. High rates of potentially infectious exposures between immunocompromised patients and their companion animals: an unmet need for education. Intern Med J. 2017 Mar;47(3):333-335.
- Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, Teh TC, Fleming S, Catalano JV, Chunilal SD, Johnston A, Opat SS, Shortt J. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv. 2016 Nov 22;1(1):31-35.
- Kaplan ZS, Zarpellon A, Alwis I, Yuan Y, McFadyen J, Ghasemzadeh M, Schoenwaelder SM, Ruggeri ZM, Jackson SP. Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. Nat Commun. 2015 Jul 23;6:7835.
- McFadyen JD, Kaplan ZS. Platelets are not just for clots.Transfus Med Rev. 2015 Apr;29(2):110-9.
- Ghasemzadeh M, Kaplan ZS, Alwis I, Schoenwaelder SM, Ashworth KJ, Westein E, Hosseini E, Salem HH, Slattery R, McColl SR, Hickey MJ, Ruggeri ZM, Yuan Y, Jackson SP. The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi. Blood. 2013 May 30;121(22):4555-66.
- Qiao J, Schoenwaelder SM, Mason KD, Tran H, Davis AK, Kaplan ZS, Jackson SP, Kile BT, Andrews RK, Roberts AW, Gardiner EE. Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). Blood. 2013 Feb 21;121(8):1479-81.
- Fong CY, Kaplan ZS. Parvovirus B19 -induced pure red cell aplasia in a heart transplant recipient.
Blood. 2012 Oct 25;120(17):3395. - Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program. 2011;2011:51-61.
- Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost. 2011 Feb;105(2):385-6.
- Kaplan ZS, Jackson SP. SR-BI and fatty platelets. Blood. 2010 Sep 16;116(11):1827-8.
- Hamilton JR, Kaplan Z, Jackson SP, Opat S. Antiplatelet therapy: present status and future prospects. Expert Opin Drug Discov. 2007 Aug;2(8):1035-40.
